4.3 Review

Targeting Cancer Stem Cells with Repurposed Drugs to Improve Current Therapies

Journal

RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY
Volume 16, Issue 2, Pages 136-160

Publisher

BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1574892816666210208232251

Keywords

Cancer stem cells; repurposed drugs; combination therapy; metformin; niclosamide; chloroquine; thioridazine

Funding

  1. New Jersey Health Foundation, USA [PC5516]
  2. American Institute for Cancer Research

Ask authors/readers for more resources

Cancer is a complex multistep process involving genetic and environmental factors leading to genetic and epigenetic changes. Cancer stem cells play a crucial role in tumor progression and are a subpopulation of tumor cells with self-renewal and differentiation abilities. Repurposing FDA-approved drugs to target resistant cancer cells, such as CSCs, can improve cancer treatment efficacy.
Background: Cancer is a multistep process involving genetic and epigenetic changes in the somatic genome. Genetic mutations as well as environmental factors lead to the initiation, promotion, and progression of cancer. Metastasis allows cancer cells to spread via circulatory and lymphatic systems; secondary tumorigenesis typically leads to a fatal outcome. Recent experimental evidence suggests that Cancer Stem Cells (CSCs) play a pivotal role in tumor progression. A tumor is heterogeneous and composed of different cell types. CSCs are a subpopulation of tumor cells possessing abilities to self-renew and differentiate. Objective: The aim of this study was to present repurposed drugs, and potential candidates, that can serve as anticancer medications intended to target resistant cancer cells, i.e. CSCs. Methods: Research publications, FDA filings, and patents have been reviewed for repurposed drugs or drug combinations that can act to improve cancer treatment and care. Results: Drugs that act against CSCs include ones approved for treatment of diabetes (metformin & thiazolidinediones), parasitic diseases (chloroquine, niclosamide, mebendazole & pyrvinium), psychotic disorders (thioridazine, clomipramine & phenothiazines), alcoholism (disulfiram), lipid disorder (statins), inflammatory diseases (tranilast, auranofin, acetaminophen & celecoxib), antibiotics (azithromycin), and other disorders. Current research findings advocate the existence of beneficial effects by combining these repurposed drugs, and also through their complementary use with conventional cancer therapies. Conclusion: Repurposing FDA-approved medications towards cancer care, by targeting the resistant CSCs, will allow for a quicker, cheaper development and approval process. A larger drug library available to physicians will allow for increased efficacy during both first-line and recurrent cancer treatments.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available